ArticleOncotarget2011
Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.
Article in Oncotarget, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- An evolution-conserved allosteric network in human tubulin governs paclitaxel efficacy.Nature chemical biology · 2026Article
- Beyond STMN1: stathmin-family control of microtubule dynamics and paclitaxel resistance in cancer.Frontiers in oncology · 2026Review
- Microtubules regulate tissue-level navigation in skin-resident macrophages.Journal of cell science · 2025Article
- Key genes and molecular mechanisms related to Paclitaxel Resistance.Cancer cell international · 2024Review
- Morphological and cytoskeleton changes in cells after EMT.Scientific reports · 2023Article
- Nitric oxide/paclitaxel micelles enhance anti-liver cancer effects and paclitaxel sensitivity by inducing ferroptosis, endoplasmic reticulum stress and pyroptosis.RSC advances · 2023Article
- High-Intensity Focused Ultrasound Enhanced Anti-Tumor Activities of Paclitaxel in Breast Cancer in vitro and in vivo.Cancer management and research · 2022Article
- Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer.Annals of translational medicine · 2020Article
- Beta3-Tubulin is Critical for Microtubule Dynamics, Cell Cycle Regulation, and Spontaneous Release of Microvesicles in Human Malignant Melanoma Cells (A375).International journal of molecular sciences · 2020Article
- Silica Coated Paclitaxel Nanocrystals Enable Neural Stem Cell Loading For Treatment of Ovarian Cancer.Bioconjugate chemistry · 2019Article
- TaxolInternational journal of molecular sciences · 2017Review
- The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.Molecular cancer research : MCR · 2017Article
- Mechanisms of resistance to cabazitaxel.Molecular cancer therapeutics · 2015Article
- Peloruside A is a microtubule-stabilizing agent with exceptional anti-migratory properties in human endothelial cells.Oncoscience · 2015Article
- Pericyte dynamics during angiogenesis: new insights from new identities.Journal of vascular research · 2014Review
- Microtubule dynamics control tail retraction in migrating vascular endothelial cells.Molecular cancer therapeutics · 2013Article
- Beyond taxol: microtubule-based treatment of disease and injury of the nervous system.Brain : a journal of neurology · 2013Review
- Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy.Theoretical biology & medical modelling · 2013Article
- The role of microtubules and their dynamics in cell migration.The Journal of biological chemistry · 2012Article
- Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.Neoplasia (New York, N.Y.) · 2012Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Class III β-tubulin (β3) is associated with tumor aggressiveness, resistance to therapy, and patient relapse. To elucidate its action, we tested β3's effect on cell migration. Expression of β3 in HeLa and MCF-7 did not alter the intrinsic rate of cell migration, but it prevented the inhibition of migration by low, nontoxic concentrations of paclitaxel. The effects on cell motility were confirmed in CHO cells with tetracycline regulated expression of β3. Cell migration and microtubule dynamics were inhibited by similar concentrations of paclitaxel, but required a 5-10 fold higher drug concentration when β3 was expressed. The directionality of migration was normal in paclitaxel, but cells spent more time in a "paused" state during which there was no net movement. These studies support a model in which paclitaxel inhibits cell migration by suppressing microtubule dynamics and β3-tubulin counteracts paclitaxel action by maintaining microtubule dynamic activity. The results provide a potential explanation for the aggressiveness of β3-expressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.